101095-67-4

Basic information

• Product Name: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea
• Synonyms: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea
• CAS NO: 101095-67-4
• Molecular Formula: C₁₅H₁₃ClN₂O₂
• Molecular Weight: 288.72892
• Mol File: 101095-67-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(101095-67-4)
• EPA Substance Registry System: 1-(4-acetylphenyl)-3-(4-chlorophenyl)urea(101095-67-4)

Safety Data

• Hazardous Substances Data: 101095-67-4(Hazardous Substances Data)

Upstream product

• 104-12-1 p-chlorphenylisocyanate 
• 99-92-3 p-aminobenzophenone 

Downstream Products

• 1067638-91-8 1-(4-chlorophenyl)-3-{4-[(2E)-3-(3,4-dichlorophenyl)prop-2-enoyl]phenyl}urea 

Relevant articles and documents

Synthesis, molecular docking, and biological activities of new cyanopyridine derivatives containing phenylurea

A new class of cyanopyridine derivatives (10a–e and 11a–e) containing the phenylurea unit was synthesized and tested against some metabolic enzymes including acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). The new cya

Synthesis of new hydrazone derivatives and evaluation of their monoamine oxidase inhibitory activity

A novel series of hydrazone derivatives were designed and synthesized. Their structures were characterized by IR, 1H NMR, 13C NMR and HR-MS spectroscopic methods. The newly synthesized compounds were evaluated for their inhibitory ac

Synthesis and Biological Evaluation of Novel 1-(4-(Hydroxy(1-oxo-1,3-dihydro-2H-inden-2-ylidene)methyl)phenyl)-3-phenylurea Derivatives

A series of novel phenylurea containing 2-benzoylindan-1-one derivatives 3a?–?3j were synthesized from the reaction of phenylurea-substituted acetophenones 1a?–?1j with phthalaldehyde 2 under mild reaction conditions in good yields. All synthesized compou

Synthesis of new 1-phenyl-3-{4-[(2E)-3-phenylprop-2-enoyl]phenyl}-thiourea and urea derivatives with anti-nociceptive activity

Chalcones or 1,3-diaryl-2-propen-1-ones are known to be useful for treating pain, inflammation, and certain diseases although their uses have not been scientifically verified. Due to the limitations of opioid and NSAID therapy, there is a continuing search for new analgesics. A series of novel new 1-phenyl-3-{4-[(2E)-3-phenylprop-2-enoyl]phenyl}-thiourea and urea derivatives were synthesized and evaluated against writhing test in mice, following the aromatic substitution pattern proposed by Topliss. The results of the preliminary bioassays indicate that compound 3 presents promising anti-nociceptive activity in acetic acid-, formalin-, and glutamate-induced pain in mice, compared with some well-known non-steroidal anti-inflammatory and analgesic drugs.

DIARYL UREAS AS CB1 ANTAGONISTS

Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays.

ARYL UREA DERIVATIVES

A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.

Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives

Phenylurenyl chalcone derivatives have been synthesized and tested as inhibitors of in vitro development of a chloroquine-resistant strain of Plasmodium falciparum, activity of the cysteine protease falcipain-2, in vitro globin hydrolysis, β-hematin forma